FOR IMMEDIATE RELEASE SK pharmteco to Showcase Breakthroughs in Drug Manufacturing at ASGCT Meeting in Baltimore RANCHO CORDOVA, Ca. (May 6, 2024) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, will unveil advancements in gene and cell therapy manufacturing through eightresearch poster presentations at the upcoming annual meeting of […]
The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of
Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), today launches AAVelocityTM,
"*" indicates required fields
